| Roger Timothy Park, DO | |
|
4088 Us-91, Hyde Park, UT 84318 | |
| (435) 563-4900 | |
| Not Available |
| Full Name | Roger Timothy Park |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 19 Years |
| Location | 4088 Us-91, Hyde Park, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295713444 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 8647453-1204 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Logan Regional Hospital | Logan, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
According to a study by the Australian Institute of Health and Welfare the number of people over 45 dying from asthma attacks has increased in the past five years. In 2006 402 people had died of asthma. 2005 had only 318 deaths related to asthma in comparison. 2006 saw a 40 percent hike from the preceding three years says the report.
Rettsyndrome.org announced their funding of two new research projects today. Jeannie T. Lee, MD, Ph.D. of Massachusetts General Hospital is awarded a two-year ANGEL Grant for $600,000 to focus on reactivating the silent X chromosome for Rett syndrome and Davut Pehlivan, MDof Baylor College of Medicine is awarded a two-year Mentored Clinical Fellowship for $250,000 to study MECP2 Duplication syndrome.
Scientists have demonstrated for the first time that it is possible to specifically modify gene expression in diseased upper motor neurons, brain cells that break down in ALS.
Mayo Clinic today announced that Mayo Medical Laboratories has signed an agreement with A&G Pharmaceutical, Inc. and will receive a non-exclusive license to certain patent rights and proprietary antibody reagents for the detection and measurement of progranulin in blood.
Biovail Corporation today commented on a proposed clinical trial recently announced by Teva Pharmaceutical Industries Ltd. According to Teva, the trial is intended to address reports of inefficacy and adverse events by consumers who switched from Wellbutrin XL® 300 mg, Biovail's FDA-approved brand of the antidepressant, bupropion hydrochloride, to Budeprion XL, Teva's generic formulation of the drug. The trial was described in a Dow Jones Newswire article dated December 2, 2009.
› Verified 9 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
According to a study by the Australian Institute of Health and Welfare the number of people over 45 dying from asthma attacks has increased in the past five years. In 2006 402 people had died of asthma. 2005 had only 318 deaths related to asthma in comparison. 2006 saw a 40 percent hike from the preceding three years says the report.
Rettsyndrome.org announced their funding of two new research projects today. Jeannie T. Lee, MD, Ph.D. of Massachusetts General Hospital is awarded a two-year ANGEL Grant for $600,000 to focus on reactivating the silent X chromosome for Rett syndrome and Davut Pehlivan, MDof Baylor College of Medicine is awarded a two-year Mentored Clinical Fellowship for $250,000 to study MECP2 Duplication syndrome.
Scientists have demonstrated for the first time that it is possible to specifically modify gene expression in diseased upper motor neurons, brain cells that break down in ALS.
Mayo Clinic today announced that Mayo Medical Laboratories has signed an agreement with A&G Pharmaceutical, Inc. and will receive a non-exclusive license to certain patent rights and proprietary antibody reagents for the detection and measurement of progranulin in blood.
Biovail Corporation today commented on a proposed clinical trial recently announced by Teva Pharmaceutical Industries Ltd. According to Teva, the trial is intended to address reports of inefficacy and adverse events by consumers who switched from Wellbutrin XL® 300 mg, Biovail's FDA-approved brand of the antidepressant, bupropion hydrochloride, to Budeprion XL, Teva's generic formulation of the drug. The trial was described in a Dow Jones Newswire article dated December 2, 2009.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Roger Timothy Park, DO 4088 Us-91, Hyde Park, UT 84318 Ph: (435) 563-4900 | Roger Timothy Park, DO 4088 Us-91, Hyde Park, UT 84318 Ph: (435) 563-4900 |
News Archive
According to a study by the Australian Institute of Health and Welfare the number of people over 45 dying from asthma attacks has increased in the past five years. In 2006 402 people had died of asthma. 2005 had only 318 deaths related to asthma in comparison. 2006 saw a 40 percent hike from the preceding three years says the report.
Rettsyndrome.org announced their funding of two new research projects today. Jeannie T. Lee, MD, Ph.D. of Massachusetts General Hospital is awarded a two-year ANGEL Grant for $600,000 to focus on reactivating the silent X chromosome for Rett syndrome and Davut Pehlivan, MDof Baylor College of Medicine is awarded a two-year Mentored Clinical Fellowship for $250,000 to study MECP2 Duplication syndrome.
Scientists have demonstrated for the first time that it is possible to specifically modify gene expression in diseased upper motor neurons, brain cells that break down in ALS.
Mayo Clinic today announced that Mayo Medical Laboratories has signed an agreement with A&G Pharmaceutical, Inc. and will receive a non-exclusive license to certain patent rights and proprietary antibody reagents for the detection and measurement of progranulin in blood.
Biovail Corporation today commented on a proposed clinical trial recently announced by Teva Pharmaceutical Industries Ltd. According to Teva, the trial is intended to address reports of inefficacy and adverse events by consumers who switched from Wellbutrin XL® 300 mg, Biovail's FDA-approved brand of the antidepressant, bupropion hydrochloride, to Budeprion XL, Teva's generic formulation of the drug. The trial was described in a Dow Jones Newswire article dated December 2, 2009.
› Verified 9 days ago
Casey Mckay Green, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 4088 N Highway 91, Hyde Park, UT 84318 Phone: 435-563-4888 Fax: 435-563-4832 | |
Jonathan Terry Jenkins, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4088 N Highway 91, Hyde Park, UT 84318 Phone: 435-563-4888 | |
Jason Harper, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4088 N Highway 91, Hyde Park, UT 84318 Phone: 435-563-4900 Fax: 435-563-4952 |